Myasthenia Gravis Treatment: A Complete Guide to IVIG, Vyvgart, Ultomiris, and Beyond

Myasthenia gravis (MG) is an autoimmune neuromuscular disease that causes fluctuating muscle weakness and fatigue. The treatment landscape has expanded dramatically in recent years, moving well beyond steroids and IVIG to include targeted therapies like Vyvgart (efgartigimod), Ultomiris (ravulizumab), and Soliris (eculizumab). This guide covers the full range of options, when each is typically used, and how to navigate conversations with a care team about what might work best.

What Is Myasthenia Gravis?

There was a time when a diagnosis of myasthenia gravis carried a grim prognosis. The name itself comes from Latin and Greek roots meaning “grave muscle weakness.” Today, thanks to a dramatically expanded arsenal of treatments, most people with MG can lead full, active lives. But getting there requires understanding the disease and knowing what treatment options exist.

Myasthenia gravis is caused by antibodies that attack the communication point between nerves and muscles, called the neuromuscular junction. In about 85% of patients, these antibodies target the acetylcholine receptor (AChR), the protein that allows nerve signals to tell muscles to contract. When these receptors are blocked or destroyed, muscles cannot respond normally to nerve commands, leading to weakness that characteristically worsens with activity and improves with rest.

MG affects an estimated 14 to 20 per 100,000 people in the United States, according to the American Academy of Neurology. It can occur at any age but has two peak onset periods: women in their 20s and 30s, and men in their 60s and 70s.

Symptoms and Classification

MG symptoms are defined by their fluctuating nature. Weakness comes and goes. It worsens with repeated use of a muscle and improves after rest. This pattern is nearly unique to MG and is a major diagnostic clue.

Ocular Myasthenia

About half of all MG patients first notice problems with their eyes: drooping eyelids (ptosis), double vision (diplopia), or both. In roughly 15% of patients, the disease stays confined to the eye muscles. This is called ocular myasthenia gravis. While not life-threatening, it can significantly impact daily activities like driving and reading.

Generalized Myasthenia

In the majority of patients, weakness eventually spreads beyond the eyes to affect:

• Facial muscles (difficulty smiling, chewing, or speaking clearly)
• Neck and limb muscles (difficulty holding up the head, climbing stairs, lifting objects)
• Throat muscles (trouble swallowing, nasal speech)
• Breathing muscles (shortness of breath, particularly when lying down)

First-Line Treatments

Acetylcholinesterase Inhibitors

Pyridostigmine (Mestinon) is usually the first medication prescribed. It does not change the underlying disease. Instead, it works by preventing the breakdown of acetylcholine (the chemical messenger at the neuromuscular junction), giving the remaining functional receptors more opportunity to receive signals. Think of it as turning up the volume when some of the speakers are broken.

Pyridostigmine provides symptomatic relief within 30 to 60 minutes of taking a dose and typically wears off within 3 to 5 hours. Side effects can include abdominal cramping, diarrhea, and increased salivation. For some patients with mild disease, pyridostigmine alone provides adequate control.

Corticosteroids

When pyridostigmine is not sufficient, prednisone is typically the next step. Steroids suppress the immune system broadly and can produce significant improvement in MG, but with familiar long-term costs: weight gain, bone loss, diabetes risk, mood changes, and vulnerability to infections.

A critical nuance: steroids can temporarily worsen MG symptoms during the first 1 to 2 weeks of treatment before improvement begins. For this reason, many neurologists start at a low dose and increase gradually, or initiate steroids in a hospital setting for patients with more severe disease.

Immunosuppressive Agents

• Azathioprine: Well-studied in MG, but takes 6 to 18 months for full effect. Used as a long-term steroid-sparing agent.
• Mycophenolate mofetil: Widely used despite mixed results in clinical trials. Many neurologists report clinical benefit even though trial data was inconclusive.
• Cyclosporine and tacrolimus: Options for patients who do not respond to azathioprine or mycophenolate.

IVIG and Plasma Exchange

Both IVIG and plasma exchange (also called plasmapheresis, or PLEX) are used for MG exacerbations, pre-surgical preparation, and as bridge therapy. They work differently but serve similar roles in the treatment plan.

IVIG for Myasthenia Gravis

IVIG delivers a concentrated dose of antibodies that modulate the immune system. For MG, it is typically given at 2 g/kg over 2 to 5 days. Improvement often begins within a week, peaks at 2 to 4 weeks, and lasts 3 to 6 weeks. Some patients receive IVIG on a regular maintenance schedule, while others use it only during flares.

IVIG’s advantages include ease of administration (no special vascular access needed), the ability to give it at home through home infusion, and a generally favorable side effect profile compared to plasma exchange. Common side effects include headache, nausea, and fatigue. For a detailed look at side effects, see the IVIG side effects guide.

Plasma Exchange (PLEX)

Plasma exchange physically removes the harmful antibodies from the blood. Blood is drawn, the plasma (which contains antibodies) is separated and discarded, and the blood cells are returned with replacement fluid. Improvement is often faster than with IVIG, beginning within days, but also wears off within weeks.

PLEX requires specialized vascular access (usually a central venous catheter) and is typically performed in a hospital or specialized outpatient center. It carries risks including blood pressure drops, infection from the catheter, and electrolyte imbalances.

Newer Targeted Therapies

The past few years have brought a revolution in MG treatment. These newer therapies target specific immune mechanisms rather than broadly suppressing the entire immune system, offering the potential for better efficacy with fewer side effects.

Vyvgart (Efgartigimod)

Approved by the FDA in 2021 for generalized MG in adults who are AChR antibody-positive, Vyvgart works by reducing levels of IgG antibodies in the blood, including the pathogenic antibodies that attack the neuromuscular junction. It blocks a receptor called FcRn, which normally recycles antibodies and keeps their levels high. By blocking this recycling process, Vyvgart causes antibody levels to drop rapidly.

Vyvgart is given as an intravenous infusion over approximately one hour, once weekly for four weeks per treatment cycle. Cycles can be repeated based on clinical response. A subcutaneous version (Vyvgart Hytrulo) is also available, allowing patients to inject the medication at home rather than requiring IV infusion.

Ultomiris (Ravulizumab)

Approved for generalized MG in AChR antibody-positive adults in 2022, Ultomiris is a complement inhibitor. It blocks a protein called C5 in the complement system, which is part of the immune cascade that damages the neuromuscular junction. By stopping this complement-driven destruction, Ultomiris protects the acetylcholine receptors.

A major practical advantage of Ultomiris is its dosing schedule: after an initial loading dose, it is given as an intravenous infusion every 8 weeks. This is significantly less frequent than its predecessor, Soliris (eculizumab), which requires infusion every 2 weeks.

Soliris (Eculizumab)

Soliris was the first complement inhibitor approved for MG (in 2017). It works through the same mechanism as Ultomiris but requires infusions every 2 weeks. Many patients who were well-controlled on Soliris have transitioned to Ultomiris for the convenience of less frequent dosing.

Rituximab

Though not FDA-approved for MG, rituximab is used off-label, particularly in patients with MuSK antibody-positive MG (a subtype accounting for about 5-8% of MG cases). MuSK-positive MG tends to be more difficult to treat with conventional therapies, and rituximab has shown remarkable effectiveness in this population, with some patients achieving long-lasting remission.

Treatment Comparison Table

Thymectomy

The thymus gland, located behind the breastbone, plays a role in MG in many patients. About 10-15% of MG patients have a thymoma (tumor of the thymus), and in these cases, surgical removal (thymectomy) is clearly indicated regardless of other treatment decisions.

For AChR antibody-positive patients without a thymoma, the landmark MGTX trial published in 2016 demonstrated that thymectomy plus prednisone led to better outcomes than prednisone alone over a 3-year period, including lower steroid doses and fewer immunosuppressant requirements. Thymectomy is now widely recommended for generalized AChR-positive MG patients under age 65, though the benefits appear to extend to older adults as well.

Thymectomy is typically performed minimally invasively (robot-assisted or video-assisted) and requires a hospital stay of 1 to 3 days. The full benefits may not be apparent for 1 to 2 years after surgery.

Myasthenic Crisis

Approximately 15-20% of MG patients will experience at least one myasthenic crisis, a life-threatening worsening of weakness that impairs breathing to the point where mechanical ventilation may be needed. Crisis can be triggered by infections, surgery, certain medications (some antibiotics, beta-blockers, magnesium), or simply worsening disease.

Treatment for crisis is IVIG or plasma exchange, administered urgently alongside supportive care in an intensive care unit. Recovery from crisis typically takes days to weeks, after which the maintenance treatment plan is usually escalated to prevent recurrence.

Prognosis and Living Well

The outlook for myasthenia gravis has transformed. With current treatments, life expectancy for MG patients is essentially normal, and most patients achieve a good quality of life. However, MG rarely “goes away” completely. It is typically a lifelong condition that requires ongoing management.

What does living well with MG look like in practice?

• Finding the right treatment combination: This often takes time and patience. What works well for one person may not work for another. Do not be discouraged by the process.
• Monitoring and adjustment: MG can fluctuate unpredictably. Regular follow-up with a neurologist experienced in MG is essential.
• Knowing your triggers: Heat, stress, illness, and certain medications can worsen MG. Learning to recognize and manage personal triggers makes a real difference.
• Planning for surgery: If surgery of any kind is needed, the anesthesiologist must know about MG because certain anesthetic agents affect MG patients differently.
• Exploring newer options: The treatment landscape continues to evolve. If current treatment is not providing adequate control, ask about the newer targeted therapies. Review insurance coverage options early to understand the financial implications.

“Myasthenia gravis is not the disease it was 30 years ago. Patients today have options their predecessors could not have imagined. The challenge is no longer whether effective treatment exists — it is ensuring every patient has access to the right treatment for their specific disease.”